Related Experiment Video
Updated: Mar 2, 2026
04:12
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
Published on: January 19, 2024
1.7K
Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders.
George Badavanis1, Efstathia Pasmatzi1, Alexandra Monastirli2
1Department of Dermatology, School of Medicine, University of Patras, Patra,Greece.
Current Drug Safety
|May 20, 2017
Summary
Biologic agents offer advanced treatment for immune-mediated inflammatory disorders but carry risks. This review details the cutaneous and systemic side effects of these important dermatotherapy drugs.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Biologic agents target specific immune pathways for inflammatory disorders like psoriasis.
- These targeted therapies have become crucial in modern dermatotherapy, offering alternatives for treatment-resistant patients.
- The increased use of biologics necessitates a thorough understanding of their safety profiles.
Purpose of the Study:
- To review the cutaneous and systemic side effects of all biologic agents used in systemic dermatotherapy.
- To enhance clinician awareness of the safety risks associated with biologics.
- To support informed, personalized drug selection and therapeutic decisions.
Main Methods:
- Literature review based on Medline and Scopus databases.
- Inclusion of data from manufacturing companies.
- Comprehensive analysis of reported side effects for all utilized biologic agents.
Main Results:
- Biologic agents, while effective, are associated with significant immunosuppressive potential.
- Serious and potentially fatal side effects have been reported, leading to drug withdrawals.
- A wide spectrum of cutaneous and systemic adverse events requires careful monitoring.
Conclusions:
- Understanding the full range of biologic side effects is critical for safe dermatologic practice.
- Clinicians must be vigilant in monitoring patients for adverse events.
- Personalized risk-benefit assessment is essential for optimal patient outcomes with biologic therapies.
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
3.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.4K
01:30Skin Cancer
6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
312
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
312
01:23Skin Diseases and Disorders
5.9K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
01:01Hypersensitivity Reactions: Cytolytic Reactions
72
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
72